Relief Therapeutics Holding Balance Sheet Health

Financial Health criteria checks 3/6

Relief Therapeutics Holding has a total shareholder equity of CHF94.4M and total debt of CHF1.7M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are CHF125.8M and CHF31.4M respectively.

Key information

1.8%

Debt to equity ratio

CHF1.69m

Debt

Interest coverage ratio	n/a
Cash	CHF12.80m
Equity	CHF94.37m
Total liabilities	CHF31.41m
Total assets	CHF125.78m

Recent financial health updates

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

May 05

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Oct 04

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Apr 23

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Sep 25

Recent updates

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

May 05

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Oct 04

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Apr 23

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Sep 25

We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

Jan 13

Financial Position Analysis

Short Term Liabilities: RLF's short term assets (CHF16.4M) exceed its short term liabilities (CHF7.1M).

Long Term Liabilities: RLF's short term assets (CHF16.4M) do not cover its long term liabilities (CHF24.3M).

Debt to Equity History and Analysis

Debt Level: RLF has more cash than its total debt.

Reducing Debt: RLF's debt to equity ratio has reduced from 4.9% to 1.8% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if RLF has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RLF has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Relief Therapeutics Holding Balance Sheet Health

Financial Health criteria checks 3/6

Key information

Recent financial health updates

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Recent updates

New minor risk - Financial data availability

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

Less than half of directors are independent

Relief Therapeutics Holding Sa Announces CEO Changes

First half 2023 earnings released: CHF5.10 loss per share (vs CHF2.55 loss in 1H 2022)

New major risk - Financial position

Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding

Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa

RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer

No independent directors

Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer

Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago

Relief Therapeutics Holding AG has filed an IPO.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Relief Therapeutics Expands U.S. Commercial Team

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022

Price target decreased to CHF0.41

No independent directors

Relief Therapeutics Holding AG Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Relief Therapeutics Holding SA Files Trademark Application for RLF-100 with the U.S. Patent and Trademark Office

Relief Therapeutics Holding AG Approves Election of Michelle Lock as New Member of the Board of Directors

NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics

Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-Induced Pneumonitis

Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil

Chief Commercial Officer Christiaan L. J. Stijnen has left the company

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Relief Therapeutics Holding AG (SWX:RLF) completed the acquisition of APR Applied Pharma Research s.a.

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Relief Provides Update on Progress and Plans with Acer-001 for the Treatment of Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) signed binding term sheet to acquire APR Applied Pharma Research s.a. for CHF.

New 90-day low: CHF0.27

Relief Therapeutics Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure Among Critically Iii Patients with Covid-19

NeuroRx and Relief Therapeutics Holding AG Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19

Director has left the company

RELIEF THERAPEUTICS Holding AG Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors

Relief Therapeutics Holding AG Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients

New 90-day high: CHF0.46

Relief Therapeutics Holding Ag and Acer Therapeutics Inc. Announces the Companies Have Signed an Option Agreement

Relief Therapeutics Holding AG (SWX:RLF) signed a binding term sheet to acquire AdVita Lifescience GmbH for €45 million.

We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

NeuroRx, Inc. and Relief Therapeutics Holding AG Conclude Enrollment in Their Phase 2B/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

Relief Therapeutics Holding Ag Appoints Christiaan L.J.J. Stijnen as Chief Commercial Officer

NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

NeuroRx, Inc. and Relief Therapeutics Holding AG Announces Initial Successful Results from Expanded Access Use of RLF-100(TM) (Aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity

NeuroRx and Relief Therapeutics Announce Enrollment of 150 Patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

NeuroRx, Inc. and Relief Therapeutics Holdings AG Announces Continuation of RLF-100™ Trial for Treatment of COVID-19 Respiratory Failure

New 90-day low: CHF0.35

NeuroRx, Inc. and Relief Therapeutics Holding AG Announce Topline Efficacy Data from Patients Treated with RLF-100™

Relief Therapeutics Holding AG Appoints Jack Weinstein as Chief Financial Officer, Effective Immediately

Relief Therapeutics Holding AG to Report Fiscal Year 2020 Results on Apr 30, 2021

Relief Therapeutics Holding AG announced that it has received CHF 17.9 million in funding from Global Emerging Markets

Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners

Relief Therapeutics Holding AG to Report First Half, 2020 Results on Sep 15, 2020